Research & Development
FDA accepts Genentech application for Lunsumio and Polivy combination in large B-cell lymphoma
18 June 2026 - Biotechnology company Genentech, a member of the Roche Group (SIX: RO, ROG) (OTCQX: RHHBY), said on Thursday that the US Food and Drug Administration (FDA) has accepted its supplemental...
Lupin announces US launch of Azilsartan Medoxomil Tablets
18 June 2026 - India-based global pharmaceutical company Lupin Limited (BSE:500257) (NSE:LUPIN) announced on Thursday the launch of Azilsartan Medoxomil Tablets, 40mg and 80mg in the United States fol...
Akeso reports Phase II data for ligufalimab in AML
...
Innoviva Specialty Therapeutics signs licensing agreement with Dr. Reddy's for XACDURO international expansion
16 June 2026 - Innoviva Specialty Therapeutics, a subsidiary of Innoviva Inc (Nasdaq:INVA) focused on innovative therapies in critical care and infectious disease, said on Tuesday that it has entered ...
Halia Therapeutics' ofirnoflast granted FDA Fast Track designation for lower-risk myelodysplastic syndromes
16 June 2026 - Clinical-stage biotechnology company Halia Therapeutics Inc announced on Monday that the US Food and Drug Administration (FDA) has granted Fast Track designation to ofirnoflast (HT-6184...
Inhibrx's ozekibart BLA accepted by FDA for chondrosarcoma treatment
15 June 2026 - Inhibrx Biosciences Inc (Nasdaq: INBX) disclosed on Monday that it has received U.S. Food and Drug Administration acceptance of its Biologics License Application for ozekibart (INBRX-10...